Keywords: آنتی بادی ضد دارو; nSMOL; Anti-drug antibodies; Bioanalysis; LC-MS/MS;
مقالات ISI آنتی بادی ضد دارو (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibodies; AMPK; 5â² adenosine monophosphate-activated protein kinase; aHUS; atypical hemolytic uremic syndrome; AMD; age-related macular degeneration; APC; antigen presenting cells; AT; anaphylatoxin; BTK; Bruton's tyrosine kinase; C1q
Keywords: آنتی بادی ضد دارو; DILI; Immune-mediated; Tolerance; Antigen; Immune cells homing; DILI; drug-induced liver injury; HLA; human leukocyte antigen; APCs; antigen presenting cells; DCs; dendritic cells; LSECs; liver sinusoidal endothelial cells; KCs; Kupffer cells; APAP; aceta
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibodies; CHMP; Committee for Medicinal Products for Human Use; DIN; Drug Identification Number; ECCO; European Crohn's and Colitis Organisation; EMA; European Medicines Agency; FDA; Food and Drug Administration; INN; International Nonp
Keywords: آنتی بادی ضد دارو; Therapeutic drug monitoring; Biologics; Anti-tumor necrosis factor; Drug concentrations; Anti-drug antibodies; Crohn's disease; Inflammatory bowel disease;
Keywords: آنتی بادی ضد دارو; Anti-drug antibodies; Neutralizing antibodies; Bioassay; Luciferase; Interferon beta; Multiple sclerosis;
Keywords: آنتی بادی ضد دارو; Cut point; Pre-existing antibodies; Biopharmaceuticals; Anti-drug antibodies; Immunogenicity; Immunotoxin;
Keywords: آنتی بادی ضد دارو; Protein formulation; immunology; adsorption; aggregates; vaccine adjuvants; anti-drug antibodies; tolerance;
Keywords: آنتی بادی ضد دارو; ADA; Anti-drug antibody(ies); ADCC; Antibody-dependent cellular cytotoxicity; AE; Adverse event; CBA; Cell-based assay; CDC; Complement dependent cytotoxicity; CLB; Competitive ligand binding; EIP; European Immunogenicity Platform; EIP-AWG; European Immun
Keywords: آنتی بادی ضد دارو; 5-FU; 5-fluorouracil; API; active pharmaceutical ingredient; ADA; anti-drug antibodies; CSE; control standard endotoxin; CTL; cytotoxic T lymphocytes; CARPA; complement activation-related pseudoallergy; CHAPS; 3-[(3-Cholamidopropyl)dimethylammonio]-1-;
Keywords: آنتی بادی ضد دارو; Crohn's disease; Optimising therapy; Thiopurine methyl transferase; Anti-TNF; Thiopurines; Azathioprine metabolites; Anti-TNF drug levels; Anti-drug antibodies; Corticosteroids; Methotrexate;
Keywords: آنتی بادی ضد دارو; Adalimumab; Immunogenicity; Anti-drug antibodies; Human monoclonal antibodies; Anti-idiotype Antibodies
Keywords: آنتی بادی ضد دارو; Zwitterionic materials; Polymer-drug conjugates; Anti-drug antibodies
Utilité pratique de la surveillance de l'immunogénicité des anticorps monoclonaux en thérapeutique dans la polyarthrite rhumatoïde
Keywords: آنتی بادی ضد دارو; Anticorps monoclonaux; Polyarthrite rhumatoïde; Immunogénicité; Anticorps anti-médicament; Monoclonal antibodies; Rheumatoid arthritis; Immunogenicity; Anti-drug antibodies;
Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab
Keywords: آنتی بادی ضد دارو; Bioavailable adalimumab; Anti-drug antibodies; Quantitative and targeted proteomics; TNFα; anti-tumor necrosis factor alpha; ADAbs; anti-drug antibodies; mAbs; monoclonal antibodies; RA; rheumatoid arthritis; IBD; inflammatory bowel disease; ISTD; intern
Pharmacokinetics of human recombinant C1-esterase inhibitor and development of anti-drug antibodies in healthy dogs
Keywords: آنتی بادی ضد دارو; AUC; area under the curve; AUClast; area under the plasma concentration-time curve from the time of dosing to the last measurable (positive) concentration; AUC-INFobs; area under the plasma concentration-time curve from the time of dosing extrapolated to
Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients
Keywords: آنتی بادی ضد دارو; Interferon beta; Multiple sclerosis; Neutralizing antibodies; T cell; Antigenic epitope; Anti-drug antibodies;
Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study
Keywords: آنتی بادی ضد دارو; Cerliponase alfa; Enzyme replacement therapy; CLN2; Neuronal ceroid lipofuscinosis; Anti-drug antibodies; Hypersensitivity; Immunogenicity; ADA; anti-drug antibody; ICV; intracerebroventricular.; ML; motor-language.; NAb; neutralizing anti-drug antibody.;
A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse
Keywords: آنتی بادی ضد دارو; Polyethylene glycol; Anti-drug antibodies; ADA; PEG; Anti-PEG antibodies; PBPK;
A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers
Keywords: آنتی بادی ضد دارو; MEDI8852; Monoclonal antibody; Influenza; Hemagglutinin; ADA; anti-drug antibodies; AUC0-t; area under the concentrationâtime curve from time 0 to last sampling time point; AUCâ; area under the plasma concentrationâtime curve from time 0 to infinity
Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
Keywords: آنتی بادی ضد دارو; Mucopolysaccharidosis type I; Enzyme replacement therapy; Immune tolerance; Laronidase; Hurler syndrome; Anti-drug antibodies;
A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis
Keywords: آنتی بادی ضد دارو; ConA; concanavalin A; Tregs; regulatory T cells; TNFα; tumor necrosis factor alpha; TNFR; TNF receptor; ADAs; anti-drug antibodies; RA; rheumatoid arthritis; Anti-TNF fusion protein; Oral tolerance; Colitis; Immune-mediated hepatitis;
Research paperRational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibodies; ATL; adult T cell leukemia; dsFv; disulfide stabilized variable fragment; PE38; Pseudomonas exotoxin A; PBMC; peripheral mononuclear cells; RIT; recombinant immunotoxin; R-PE; phycoerythrin-tagged anti-CD25 antibody; scFv; singl
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study
Keywords: آنتی بادی ضد دارو; Alzheimer's disease; Antibody; Amyloid; Pharmacokinetics; Pharmacodynamics; Ponezumab; PIB; Safety; Tolerability; Anti-drug antibodies;
Engineering less immunogenic and antigenic FVIII proteins
Keywords: آنتی بادی ضد دارو; Factor VIII; Epitopes; Anti-drug antibodies; Immunogenicity; Antigenicity;
Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab
Keywords: آنتی بادی ضد دارو; Infliximab; Anti-drug antibodies; Crohn's disease; HMSA;
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy
Keywords: آنتی بادی ضد دارو; Immunotoxin; De-immunization; Pharmacokinetics; Lung cancer; Patient-derived xenografts; Targeted therapy; ADAs; anti-drug antibodies; CI; confidence interval; Fab; antibody fragment comprising the variable and the first constant domains; Fv; antibody fra
Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; ALT; alanine aminotransferase; AST; aspartate aminotransferase; BSA; bovine serum albumin; BUN; blood urea nitrogen; CP; cut point; CREA; creatinine; FcγR; Fc-gamma receptor; HQC; high quality control sample; HPLC; high pressure
Anti–tumor necrosis factor-α therapy in uveitis
Keywords: آنتی بادی ضد دارو; uveitis; tumor necrosis factor-alpha; infliximab; adalimumab; etanercept; golimumab; certolizumab; serum levels of anti–TNF-α drug; anti-drug antibodies; pharmacogenomics of anti–TNF-α therapy
Next-generation optimized biotherapeutics - A review and preclinical study
Keywords: آنتی بادی ضد دارو; ADAs; anti-drug antibodies; ADC; antibody drug conjugate; ADCC; antibody-dependent cell-mediated cytotoxicity; ATL; adult T-cell leukemia-lymphoma; CCR4; CC chemokine receptor 4; CDC; complement-dependent cytotoxicity; CDR; complementary determining regio
Increased sensitivity of SPR assays in plasma through efficient parallel assay optimization
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibodies; DOE; design of experiments; LOD; limit of detection; Immunogenicity; Surface plasmon resonance (SPR) assay; Therapeutic antibody; Anti-drug antibodies (ADAs); Multivariate design of experiments (DoE); Non-specific binding from p
ReviewT-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Keywords: آنتی بادی ضد دارو; Td; T-cell dependent, thymus dependent; T; thymus; ADA; anti-drug antibodies; Ti; T-cell independent; APC; antigen-presenting cells; HLA; human leukocyte antigen; MHC; major histocompatibility complex; TCR; T cell receptor; Treg; regulatory T cells; FVIII
A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers
Keywords: آنتی بادی ضد دارو; Anti-PEG antibodies; PEGylated biotherapeutics; Bridging immunogenicity ELISA; Anti-drug antibodies; Universal PEG immunogenicity test method
Safety evaluation of biological drugs: What are toxicology studies in primates telling us?
Keywords: آنتی بادی ضد دارو; Biological drugs; Monoclonal antibodies; Recombinant proteins; Toxicity; Repeat dose; Primate; Anti-drug antibodies;
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients
Keywords: آنتی بادی ضد دارو; Adalimumab; Immunogenicity; Drug interference; Anti-drug antibodies; Anti-TNFα treatment;